+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating whether combining pasritamig with docetaxel can extend the time before disease progression, measured by scans or death, compared to docetaxel alone in adults with metastatic castration-resistant prostate cancer. This type of prostate cancer continues to grow despite low male hormone levels. The study is a Phase 3 randomized trial designed to compare these treatments in this patient population. Participants are assigned to one of two groups. One group receives pasritamig together with docetaxel until disease progression or treatment end. The other group receives docetaxel plus prednisone or prednisolone as background medication. The study uses imaging scans and other criteria to monitor disease progression. The study treatment continues until certain protocol-defined endpoints are met. During the study, participants undergo various scans including CT, MRI, and bone scans to assess disease status. Researchers monitor progression-free survival and other outcomes such as overall survival, symptom progression, and quality of life using questionnaires. Safety is tracked by recording adverse events, lab abnormalities, and treatment side effects. Follow-up lasts up to about four and a half years, allowing comprehensive evaluation of treatment impact and safety.

Age: 18Years +All GendersPhase 3
165 locations
R

Actively Recruiting

This trial evaluates the combination of Navlimetostat BMS-986504, pembrolizumab, and chemotherapy compared to placebo with pembrolizumab and chemotherapy in adults with first-line metastatic non-small cell lung cancer having homozygous MTAP deletion. The study is a randomized, double-blind Phase 23 trial sponsored by Bristol-Myers Squibb, aiming to understand treatment benefits in this specific patient group. Participants must have measurable metastatic NSCLC, no prior systemic therapy for metastatic disease, and meet performance status criteria. Participants receive either Navlimetostat plus pembrolizumab and chemotherapy or placebo plus pembrolizumab and chemotherapy. Chemotherapy may include drugs such as cisplatin, carboplatin, pemetrexed, paclitaxel, or nab-paclitaxel, given on specified days at specified doses. Treatment is administered in the first-line metastatic setting, with detailed dosing and combinations determined by study protocols. Randomization assigns participants to one of multiple arms to compare the investigational combination against placebo. Throughout the study, participants are monitored for progression-free survival up to 2 years and 5 years, overall survival up to 5 years, as well as response rates and safety outcomes including adverse events and laboratory abnormalities. Assessments follow RECIST v1.1 criteria with independent and investigator reviews. Safety monitoring includes tracking serious adverse events and treatment-related side effects up to 90 days after treatment ends. The study duration extends to the primary completion date in August 2031, with ongoing evaluations for up to 5 years post-treatment.

Age: 18Years +All GendersPhase 2Phase 3
321 locations
P

Actively Recruiting

Researchers are comparing the effects of two treatment combinations in adults with stage IV or recurrent non-squamous non-small cell lung cancer NSCLC that has a PD-L1 expression of 1% or higher. This phase 3 trial investigates whether Nivolumab and Relatlimab combined with chemotherapy works differently than Pembrolizumab with chemotherapy as first-line treatment for this condition. The study is sponsored by Bristol-Myers Squibb and uses a randomized parallel design. Participants will be assigned to one of two groups one group receives Nivolumab and Relatlimab with chemotherapy drugs, while the other group receives Pembrolizumab with chemotherapy. Chemotherapy may include drugs such as Carboplatin, Pemetrexed, or Cisplatin, given at specified doses on specific days. Treatment schedules and doses are carefully planned, and participants are treated during the trial period. During the study, participants undergo regular assessments to measure overall survival, progression-free survival, response rates, and duration of response, with follow-up lasting up to five years. Researchers also track adverse events and immune-related side effects for up to 2.5 years. Quality of life is monitored through symptom questionnaires. Assessments include imaging scans and laboratory tests to evaluate disease status and treatment effects. The total duration of participation may extend over several years to capture long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
329 locations
S

Actively Recruiting

Researchers are exploring new treatment options for people with advanced colorectal cancer that has spread or cannot be removed by surgery. This cancer type, affecting the colon or rectum, sometimes involves problems with the bodys DNA repair system called dMMR or a condition called MSI. These issues can cause cancer cells to rely on a protein called Werner helicase to survive. Blocking this protein might help stop cancer growth with less harm to healthy cells. This Phase 2 study evaluates a drug named VVD-133214 that blocks Werner helicase, combined with pembrolizumab, an immunotherapy drug approved to help the immune system attack cancer cells. Participants in this trial will receive oral VVD-133214 along with pembrolizumab given by intravenous infusion every three weeks. The study compares this combination to pembrolizumab alone to find the best dose of VVD-133214 and to assess whether the combination works better. Participants will receive VVD-133214 as long as it remains helpful without causing serious side effects, while pembrolizumab treatment will continue for up to two years. Participants may stop treatment at any time. During the trial, participants will have regular visits for tests, scans, and health check-ups to monitor how their cancer responds and to track any new or worsening medical problems. After stopping treatment, follow-up visits will occur 30 days after the last VVD-133214 dose and 100 days after the last pembrolizumab dose. Long-term follow-up visits will continue every 90 days as long as participants agree to remain in the study. The main outcome measured is the progression-free survival rate at six months, with safety and other response measures also monitored throughout up to about 36 months.

Age: 18Years +All GendersPhase 2
122 locations
E

Actively Recruiting

Researchers are evaluating treatments for people with advanced non-small cell lung cancer NSCLC that has spread or cannot be controlled by current therapies. This study focuses on patients whose cancer cells have specific changes called HER2 mutations, which cause abnormal cell growth. The main goal is to compare the effectiveness and safety of a new drug called sevabertinib against the standard treatment for this condition. Participants will be randomly assigned to one of two groups one group will take sevabertinib tablets twice daily, and the other will receive the current standard treatment, which includes pembrolizumab combined with platinum-based chemotherapy given by vein infusion every 21 days. Those on standard treatment may switch to sevabertinib if their cancer worsens. Treatment continues as long as participants benefit and do not have severe side effects. During the study, participants will undergo scans like CT, PET, MRI, or X-rays to monitor their cancer. Health assessments include blood and urine tests, heart checks using electrocardiograms and echocardiograms, pregnancy tests when needed, and evaluations of how participants feel and any medical problems they experience. The main outcome measured is how long participants live without their cancer progressing, with other outcomes including overall survival and response rates. The study lasts up to about 4 years, with ongoing monitoring for safety and patient well-being.

Age: 18Years +All GendersPhase 3
279 locations
C

Actively Recruiting

Researchers are investigating the effects of heated water-based exercise compared to land-based exercise on blood pressure and various health measures in older adults with hypertension. This study focuses on individuals over 60 years old with hypertension, aiming to assess how these exercise types impact arterial stiffness, endothelial function, metabolic and inflammatory markers, and functional capacity. The goal is to understand if exercising in a heated swimming pool offers unique benefits over traditional land exercises for managing hypertension and related health factors. Participants will be randomly assigned to one of three groups heated water-based exercise HEx, land-based exercise LEx, or a control group that maintains usual physical activity without starting new exercise programs. Both exercise groups will train three times a week for 12 weeks. HEx sessions include warm-up, aerobic exercise, resisted exercises targeting various muscle groups, and stretching, all performed in a heated pool. LEx sessions follow a similar structure but use treadmills, exercise bikes, fitness machines, and free weights on land. The control group receives guidance to maintain their usual activity levels. Throughout the study, participants will undergo assessments at the start, after 12 weeks, and after 24 weeks. These evaluations include blood pressure measurements, arterial stiffness, vascular function tests, exercise capacity assessments, muscle strength, flexibility, balance, and endurance tests. Researchers will monitor adherence to exercise sessions and track any changes in medication or health status. The study aims to provide detailed insight into the physiological and functional effects of these exercise programs in older adults with hypertension.

Age: 60Years +All GendersPhase Not Applicable
1 location
C

Actively Recruiting

Researchers are comparing antimicrobial photodynamic therapy aPDT combined with scaling and root planing to scaling and root planing alone for treating periodontal disease in patients with obesity. The study aims to find out if adding aPDT improves periodontal health and reduces inflammation, as well as to examine differences in the protein makeup of gingival fluid after treatment. This interventional trial is led by the University of Sao Paulo and involves adults aged 18 to 70 with periodontal disease and obesity. Participants are randomly assigned to one of two groups one receives scaling and root planing followed by aPDT using methylene blue and a red laser, while the other receives only scaling and root planing. Both treatments are non-surgical procedures performed to clean the teeth and gums. The study uses a double-blind design to reduce bias. Participants will be evaluated at the start of the study and then again at 1, 3, and 6 months after treatment. Assessments include measuring probing depth, clinical attachment level, bleeding on probing, and changes in gingival fluid proteins. These measures help researchers understand the impact of the treatments on periodontal health. The total follow-up period lasts six months, during which safety and treatment effects are monitored.

Age: 18Years - 70YearsAll GendersPhase Not Applicable
1 location
S

Actively Recruiting

Healthy Volunteer

Researchers are studying how beetroot extract affects blood pressure and muscle oxygen levels during exercise in older women with high blood pressure. This trial focuses on the immediate effects of beetroot extract supplementation to understand its impact on cardiovascular and metabolic responses during aerobic exercise. The study is important because hypertension is a major risk factor for heart disease in this group, and dietary nitrate from beetroot might improve exercise tolerance and vascular health. Participants will take part in four sessions in a random order resting with placebo, resting with beetroot extract, exercising with placebo, and exercising with beetroot extract. Each beetroot dose includes about 314 mg of dietary nitrate in two capsules. The exercise sessions include a 7-minute warm-up and 30 minutes of aerobic exercise on a treadmill at 60-80% of their maximum heart rate. Rest sessions include sitting for 30 minutes while completing a food questionnaire. There is a minimum of two days between sessions to allow washout. During the study, participants blood pressure will be measured at rest, during, immediately after, and after recovery from the sessions. Muscle oxygen saturation will be continuously monitored during exercise, and markers of oxidative stress will be checked before and right after each session. The study tracks how these measures change with beetroot extract compared to placebo, providing detailed insight into its effects on exercise stress in hypertensive older women.

Age: 60Years +FEMALEPhase Not Applicable
1 location
E

Actively Recruiting

Researchers are evaluating the effectiveness of periodontal treatment combined with a tongue scraper, compared with the same treatment plus antimicrobial photodynamic therapy aPDT, in reducing bad breath halitosis in people who have periodontal disease and type 2 diabetes. The trial aims to determine if adding aPDT to conventional treatment is more effective for treating halitosis and improving periodontal health. This study is a randomized clinical trial sponsored by the University of Sao Paulo. Participants will receive one of two treatments scaling and root planing with antimicrobial photodynamic therapy applied to periodontal pockets and the tongue, or scaling and root planing with a tongue scraper only. Treatments will be given once a week for one month. After this active treatment phase, participants will attend maintenance and control visits once a month for up to six months. During the study, participants will visit the clinic weekly during treatment and monthly during follow-up. Researchers will assess halitosis from enrollment through six months, along with periodontal health measurements such as probing depth and clinical attachment level. These evaluations will help determine the added effects of aPDT compared to conventional treatment. The total participation time covers one month of active treatment plus six months of follow-up.

Age: 18Years - 70YearsAll GendersPhase Not Applicable
1 location
C

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the effects of high-intensity interval training HIIT versus moderate-intensity continuous exercise MICE, both done in heated water, on blood pressure and other related heart and vessel functions in older adults with hypertension. The study focuses on understanding how these two types of exercise impact hemodynamic and autonomic responses in this population, who often face challenges in exercising due to comorbidities or injuries. This research aims to provide insight into effective exercise strategies for managing hypertension in older individuals. The trial includes 60 participants over 60 years old with hypertension, randomly assigned to one of three groups HIIT, MICE, or a control group with no exercise. Exercise sessions are conducted in heated water at 30 to 32 C, with participants submerged up to the chest level. The HIIT program involves a warm-up followed by intervals of jogging or running alternating with walking, while the MICE program consists of continuous walking or jogging at moderate intensity. The control group remains seated in heated water without exercising. The exercise programs last for 12 weeks, followed by a 12-week observation period without exercise. Participants undergo evaluations before, during, and after the intervention, including blood pressure, arterial stiffness, endothelial function, heart rate variability, and physical and functional capacity tests. Quality of life is also assessed using questionnaires. Researchers monitor adherence to the exercise programs and measure changes in these variables after 12 and 24 weeks. The primary outcome is the change in systolic and diastolic blood pressure after 12 weeks of exercise.

Age: 60Years +All GendersPhase Not Applicable
1 location

1-10 of 11

1